| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss attributable to lineage | -64,384 | -34,603 |
| Net income (loss) attributable to noncontrolling interest | 125 | 96 |
| Issuance costs for common stock warrant liabilities | 183 | 183 |
| Loss on impairment of intangible asset | 14,840 | 14,840 |
| Loss on marketable equity securities, net | -1 | -7 |
| Accretion of income on marketable debt securities | 10 | 10 |
| Foreign currency remeasurement and other loss | - | 1,455 |
| Depreciation and amortization expense | 513 | 335 |
| Change in right-of-use assets and liabilities | -41 | -88 |
| Amortization of intangible assets | 0 | 0 |
| Stock-based compensation | 3,654 | 2,455 |
| Change in fair value of warrant liability | 36,992 | 10,435 |
| Foreign currency remeasurement | 1,721 | - |
| Accounts receivable | -511 | -381 |
| Prepaid expenses and other current assets | -1,077 | -1,271 |
| Accounts payable and accrued liabilities | -188 | -459 |
| Deferred revenue | -5,593 | -3,813 |
| Net cash used in operating activities | -14,041 | -10,425 |
| Proceeds from the sale of marketable equity securities | 0 | 0 |
| Purchases of marketable debt securities | 0 | 0 |
| Maturities of marketable debt securities | 2,000 | 2,000 |
| Purchase of equipment | 123 | 111 |
| Net cash (used in) provided by investing activities | 1,877 | 1,889 |
| Proceeds from employee options exercised | 487 | 0 |
| Proceeds from exercise of warrants | 319 | - |
| Common shares received and retired for employee taxes paid | 15 | 15 |
| Proceeds from sale of common shares, net of offering costs-At The Market | 1,276 | 0 |
| Proceeds from sale of common shares, net of offering costs-Direct Financing | 0 | 0 |
| Proceeds from sale of common shares, net of offering costs-Warrants Under Registered Direct Financing | 5,232 | 5,232 |
| Payment of financed insurance premium | 684 | 452 |
| Payment of finance lease liabilities | 44 | 28 |
| Net cash provided by financing activities | 6,571 | 4,737 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 216 | 220 |
| Net decrease in cash, cash equivalents and restricted cash | -5,377 | -3,579 |
| Cash and cash equivalents at beginning of period | 46,354 | - |
| Cash and cash equivalents at end of period | 40,977 | - |
Lineage Cell Therapeutics, Inc. (LCTX)
Lineage Cell Therapeutics, Inc. (LCTX)